A study to analyse real-life patterns of use of Ibritumomab tiuxetan, and associated incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphomas
Latest Information Update: 29 Nov 2019
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 29 Nov 2019 New trial record
- 06 Nov 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.